Abstract
Objectives: This study aimed to evaluate the effect of oseltamivir and favipiravir in patients with confirmed COVID-19 on clinical outcomes and length of stay at Farmawati General Hospital, Jakarta. Methods: The cross-sectional study was conducted at Fatmawati General Hospital, Jakarta. The study sample consisted of 114 patients who met the inclusion and exclusion criteria from March to October 2020. Data were collected retrospectively using medical record data. Results: The result showed that 98 patients (86.0%) received oseltamivir, while 16 patients (14.0%) received favipiravir in this study. The mortality rate was 11.4% (13 patients), while the recovered was 88.6% (103 patients). Patients who had LoS (Length of Stay) of ≤14 days were 58.8%, while patients with LoS >14 days were 41.2%. In bivariate analysis, antivirals (oseltamivir and favipiravir) effect on clinical outcome was not statistically significant (p=0.690; OR=0.478; CI 95%=0.058–3.950). Likewise, the association between antivirals and LoS was also not statistically significant (p=0.852; OR=0.767; CI 95%=0.251–2.342). Conclusion: Antivirals were not significantly associated with clinical outcomes and length of stays in COVID-19 patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Journal of Pharmaceutical and Clinical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
